Health Basket Committee Begins 2027 Discussions Amid Budget Concerns
Translated & summarized from Haaretz by baba
Israel's Health Basket Committee for 2027 began its discussions on Monday to select new treatments. The committee received the same 650 million shekel budget as in previous years, despite rising technological and demographic demands. Delays in committee appointments have previously postponed the inclusion of new drugs, potentially increasing patient costs.
The story in 5 lines · by baba
- The 2027 Health Basket Committee began discussions Monday on new medications and technologies.
- The committee received a 650 million shekel budget, unchanged since 2023.
- The budget is questioned due to technological advancements and an aging population.
- Committee appointments were delayed, potentially pushing new treatments into February or March.
- Previous delays have caused significant financial burdens for patients.
The committee tasked with expanding Israel's health basket for 2027 convened for its initial discussions on Monday to determine which new medications and technologies will be added. The committee was allocated an additional 650 million shekels for the basket's budget, the same amount it has received since 2023. This funding level is being questioned given significant technological advancements that may require greater investment and the accelerating aging of the population, which increases medical demands.
The committee's composition for 2027 was only approved on Sunday, despite the usual practice of appointing members by the end of September and commencing discussions after the Jewish holidays. In the past three years, this delay has postponed the inclusion of newly approved treatments into the health basket until February or March. This delay could also lead to substantial financial expenses for patients requiring these medications.
